Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Fineline Cube Jun 5, 2026
Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Fineline Cube Jun 5, 2026
Company Drug

Transcenta Holdings’ TST002 Shows Positive Phase I Results for Bone Density in China

Fineline Cube May 17, 2023

China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...

Company Drug

BeiGene’s Tislelizumab Secures First Approvals Outside China Mainland in Macau

Fineline Cube May 17, 2023

BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor,...

Company Drug

Yizun Biomedicine’s CNK-UT Cell Therapy Initiates Patient Enrollment for Solid Tumor Trial

Fineline Cube May 17, 2023

Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...

Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Studies Selected for EHA Annual Meeting

Fineline Cube May 17, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...

Company Drug

Zelgen Biopharmaceuticals’ ZG0895 Receives FDA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube May 16, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Deals

Coherent Biopharma Secures $100 Million in Series B and B+ Financings for Clinical Pipeline

Fineline Cube May 16, 2023

Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared...

Company Legal / IP

Philips Agrees to $62 Million Settlement with SEC Over China Marketing Practices

Fineline Cube May 16, 2023

The US Securities and Exchange Commission (SEC) has announced that Dutch device company Philips (BVMF:...

Company Deals

Drug Farm Secures $27 Million in Series C Financing to Advance HBV Treatments

Fineline Cube May 16, 2023

Drug Farm, a Sino-US biotech company specializing in hepatitis B virus (HBV) treatments, oncology, and...

Company Medical Device

Peijia Medical Achieves Milestone with First Commercial Implants of Trilogy TAVR System in Hong Kong

Fineline Cube May 16, 2023

Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful...

Company Deals

BiOneCure Therapeutics and Nanjing Leads Biolabs Collaborate on Innovative ADCs for Solid Tumors

Fineline Cube May 16, 2023

US-based biotech company BiOneCure Therapeutics Inc. has entered into a strategic collaboration with China-based Nanjing...

Company Drug

Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study

Fineline Cube May 16, 2023

China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of...

Company Drug

Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD

Fineline Cube May 16, 2023

Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing...

Company Drug

Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy

Fineline Cube May 16, 2023

Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an...

Company Deals

Aligos Therapeutics Partners with Amoytop Biotech for Oligonucleotide Compound R&D

Fineline Cube May 16, 2023

Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership...

Company Drug

CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces

Fineline Cube May 16, 2023

The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates...

R&D

COVID-19 Disruptions Lead to Soaring Lab Monkey Prices, Impacting US Drug Development

Fineline Cube May 16, 2023

The COVID-19 pandemic has led to a significant reduction in the export of laboratory monkeys...

Company Drug

Huadong Medicine’s HDM1002 Receives FDA Approval for Clinical Trials

Fineline Cube May 16, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Company Deals

Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis

Fineline Cube May 15, 2023

China-based Rona Therapeutics Inc. and Keymed Biosciences (HKG: 2162) have unveiled a strategic collaboration aimed...

Company Deals Digital

Omron Healthcare and JD Healthcare Form Partnership to Innovate Chronic Disease Management

Fineline Cube May 15, 2023

At the China International Medical Equipment Fair (CMEF), Omron Healthcare, a leading provider of healthcare...

Company Deals

LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305

Fineline Cube May 15, 2023

Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing...

Posts pagination

1 … 538 539 540 … 678

Recent updates

  • Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
  • China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
  • Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform
  • Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
  • SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Company Drug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.